15 Nov
15 Nov
NOW APPROVED—Expanded Dosing Option for EYLEA┬« (aflibercept) Injection in Wet AMD 
06 Jun
06 Jun
REGENERON Announces an Increase in the Wholesale Acquisition Cost (WAC) Discount from 1.1% to 2.5% for Community-Based Physicians, Effective June 11
07 May
07 May
Update on Post-Marketing Reports of Intraocular Inflammation (IOI) Following Administration of EYLEA® (aflibercept) Injection
28 Feb
28 Feb
Update on Intraocular Inflammation (IOI) With Syringes Packaged in Certain Lots of EYLEA┬« (aflibercept) Injection
8 Jan
8 Jan
EYLEA4U PROGRAM: EYLEA Co-Pay Card Annual Limit Updated to Provide Increased Co-Pay Support

The 2018 New Year rings in goodness, cheer, and increased co-pay assistance for eligible patients who qualify for the EYLEA Co-Pay Card Program. Eligible patients may still pay only $5 for each treatment co-pay, but the total annual amount of assistance has now been increased from $10,000 to $15,000.

Learn more 

Important Safety Information and Indications
  • EYLEA® (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
Important Safety Information INDICATIONS

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with Neovascular (Wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in patients with DME.

Please see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

The information provided in this site is intended only for healthcare professionals in the United States. The products discussed herein may have different product labeling in different countries.